BioSpace News Archive

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place on April 12 – 15, 2021.

A prominent leader in female health, Dr. Heather Furnas, of Allegro Medspa, is adding this first-of-its-kind treatment for women to her practice. Cliovana is the fastest growing, non-invasive female sexual wellness treatment in North America.

The STARR Coalition, a non-profit dedicated to advancing mental health research, today announced a National Call to Action to Support Mental Health Research in partnership with biopharmaceutical research leaders, clinical investigators, and advocacy organizations focused on treating unmet mental health needs.

Versant Health, a leading national managed vision care company and wholly owned subsidiary of MetLife, is proud to announce Kimberly Davis as its Chief Financial Officer (CFO), effective April 1.

MedShape, Inc., the orthopedic industry leader in promoting active, adaptive healing technologies, is pleased to announce the appointment of Greg Berlet, MD as Chief Medical Officer.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.

Leading Canadian laboratory services provider partners with cyber security research community to strengthen security posture and further protect customer data

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting.

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the completion of a $43M capital raise.

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI® (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis